The Scripps Research Institute enters major five-year $100 million collaboration with Pfizer

November 30, 2006

Under the terms of the agreement, Pfizer will pay Scripps Research $100 million over a five year period, during which scientists from Pfizer and the Institute will work together to identify and perform specific projects of mutual interest.

They will jointly study and evaluate therapeutic approaches for diseases such as cancer, diabetes, and mental illnesses. They will develop new tests to rapidly validate these new therapies for potential development as possible novel treatment options that can gain regulatory approval for use in patients.

The company will pay the Institute milestones and royalties on therapeutic compounds created through the collaboration. In addition, Pfizer will have the first right to license many discoveries made at Scripps Research during the agreement.

"This collaborative process-basic biomedical research from which will grow new drugs-will advance both scientific knowledge and human health," said Scripps Research Institute President Richard A. Lerner, M.D. "It may also speed up the timeframe for translating breakthrough discoveries in the lab into treatments for currently disabling, even fatal diseases."

"Biomedical researchers share the common goal of curing diseases, whether they're conducting basic or fundamental science to understand how systems work, or applying scientific knowledge toward the invention of a potential new drug that effectively and safely confronts diseases in patients," said John LaMattina, president, Pfizer Global Research and Development. "The Scripps Research Institute's focus on targeted scientific platforms, specific areas of human disease biology and therapeutic areas complements and adds new depth to Pfizer's current research programs for many critical diseases. Leveraging the strengths the hybrid Scripps/Pfizer research teams brings new power to their ability to study and solve important relevant to uncured diseases."

The Scripps/Pfizer research teams will build a substantial collaborative portfolio of targeted disease biology projects, and biotherapeutic drug discovery efforts, drawing from resources at both organizations.
-end-
About The Scripps Research Institute

The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations, at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development. Established in its current configuration in 1961, it employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel. Scripps Research is headquartered in La Jolla, California. It also includes Scripps Florida, whose researchers focus on basic biomedical science, drug discovery, and technology development. Currently operating from temporary facilities in Jupiter, Scripps Florida will move to its permanent campus in 2009.

About Pfizer Global Research and Development

Pfizer Global Research & Development is the world's largest privately-owned biomedical research organization. Pfizer Inc discovers, develops, manufactures and markets leading prescription medicines for humans and animals. More information about Pfizer can be found at www.pfizer.com

Scripps Research Institute

Related Diseases Articles from Brightsurf:

Understanding the spread of infectious diseases
Physicists at M√ľnster University (Germany) have shown in model simulations that the COVID-19 infection rates decrease significantly through social distancing.

Parkinson's disease is not one, but two diseases
Researchers around the world have been puzzled by the different symptoms and varied disease pathways of Parkinson's patients.

New gene implicated in neuron diseases
Healthy NEMF helps the cell recycle garbled protein fragments. But several mutant forms resulted in neuromuscular, neurodegenerative or other ALS-like disease, the scientists found.

Stretching your legs may help prevent diseases such as heart diseases and diabetes
New research published today in The Journal of Physiology shows that 12 weeks of easy-to-administer passive stretching helps improve blood flow by making it easier for your arteries to dilate and decreasing their stiffness.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

How many rare diseases are there?
Dr. Tudor Oprea says a better method for classifying rare diseases will lead to improved patient care.

A vaccine against chronic inflammatory diseases
In animals, a vaccine modifying the composition and function of the gut microbiota provides protection against the onset of chronic inflammatory bowel diseases and certain metabolic disorders, such as diabetes and obesity.

Ants fight plant diseases
New research from Aarhus University shows that ants inhibit at least 14 different plant diseases.

New, noninvasive test for bowel diseases
Gut diseases such as inflammatory bowel disease (IBD) are increasingly prevalent worldwide, especially in industrialized countries.

What is known -- and not known -- about heart muscle diseases in children
Cardiomyopathies (heart muscle diseases) in children are the focus of a new scientific statement from the American Heart Association that provides insight into the diagnosis and treatment of the diseases as well as identifying future research priorities.

Read More: Diseases News and Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.